<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39226680</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>13</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2352-3964</ISSN><JournalIssue CitedMedium="Internet"><Volume>107</Volume><PubDate><Year>2024</Year><Month>Sep</Month></PubDate></JournalIssue><Title>EBioMedicine</Title><ISOAbbreviation>EBioMedicine</ISOAbbreviation></Journal><ArticleTitle>Tanomastat exerts multi-targeted inhibitory effects on viral capsid dissociation and RNA replication in human enteroviruses.</ArticleTitle><Pagination><StartPage>105277</StartPage><MedlinePgn>105277</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">105277</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ebiom.2024.105277</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2352-3964(24)00313-X</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Global cyclical outbreaks of human enterovirus infections has positioned human enterovirus A71 (EV-A71) as a neurotropic virus of clinical importance. However, there remains a scarcity of internationally approved antivirals and vaccines.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In pursuit of repurposing drugs for combating human enteroviruses, we employed a comprehensive pharmacophore- and molecular docking-based virtual screen targeting EV-A71 capsid protein VP1-4, 3C protease, and 3D polymerase proteins. Among 15 shortlisted ligand candidates, we dissected the inhibitory mechanism of Tanomastat in cell-based studies and evaluated its in vivo efficacy in an EV-A71-infected murine model.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">We demonstrated that Tanomastat exerts dose-dependent inhibition on EV-A71 replication, with comparable efficacy profiles in enterovirus species A, B, C, and D in vitro. Time-course studies suggested that Tanomastat predominantly disrupts early process(es) of the EV-A71 replication cycle. Mechanistically, live virus particle tracking and docking predictions revealed that Tanomastat specifically impedes viral capsid dissociation, potentially via VP1 hydrophobic pocket binding. Bypassing its inhibition on entry stages, we utilized EV-A71 replication-competent, 3D<sup>pol</sup> replication-defective, and bicistronic IRES reporter replicons to show that Tanomastat also inhibits viral RNA replication, but not viral IRES translation. We further showed that orally administered Tanomastat achieved 85% protective therapeutic effect and alleviated clinical symptoms in EV-A71-infected neonatal mice.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Our study establishes Tanomastat as a broad-spectrum anti-enterovirus candidate with promising pre-clinical efficacy, warranting further testing for potential therapeutic application.</AbstractText><AbstractText Label="FUNDING" NlmCategory="BACKGROUND">MOE Tier 2 grants (MOE-T2EP30221-0005, R571-000-068-592, R571-000-076-515, R571-000-074-733) and A∗STARBiomedical Research Council (BMRC).</AbstractText><CopyrightInformation>Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Therese Yien May</ForeName><Initials>TYM</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular RNA Virology and Antiviral Strategies, Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jaladanki</LastName><ForeName>Chaitanya K</ForeName><Initials>CK</Initials><AffiliationInfo><Affiliation>Bioinformatics Institute, Agency for Science, Technology and Research (A∗STAR), 30 Biopolis Street, Matrix #07-01, 138671, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Yi Hao</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>NUSMed Biosafety Level 3 Core Facility, Yong Loo Lin School of Medicine, National University of Singapore, 14 Medical Drive, 117599, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yogarajah</LastName><ForeName>Thinesshwary</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular RNA Virology and Antiviral Strategies, Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Infectious Disease Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, 117597, Singapore. Electronic address: micthiy@nus.edu.sg.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Hao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Bioinformatics Institute, Agency for Science, Technology and Research (A∗STAR), 30 Biopolis Street, Matrix #07-01, 138671, Singapore; Synthetic Biology Translational Research Program, Yong Loo Lin School of Medicine, National University of Singapore, 10 Medical Drive, 117597, Singapore; Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, 8 Medical Drive, 117596, Singapore; Duke-NUS Medical School, 8 College Rd, 169857, Singapore. Electronic address: fanh@bii.a-star.edu.sg.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chu</LastName><ForeName>Justin Jang Hann</ForeName><Initials>JJH</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular RNA Virology and Antiviral Strategies, Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; NUSMed Biosafety Level 3 Core Facility, Yong Loo Lin School of Medicine, National University of Singapore, 14 Medical Drive, 117599, Singapore; Infectious Disease Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, 117597, Singapore; Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (A∗STAR), 61 Biopolis Drive, Proteos #06-05, 138673, Singapore. Electronic address: miccjh@nus.edu.sg.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>EBioMedicine</MedlineTA><NlmUniqueID>101647039</NlmUniqueID><ISSNLinking>2352-3964</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D036022">Capsid Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="Y">Virus Replication</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="Y">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="Y">Enterovirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062105" MajorTopicYN="Y">Molecular Docking Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036022" MajorTopicYN="N">Capsid Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002213" MajorTopicYN="N">Capsid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="N">Enterovirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094405" MajorTopicYN="N">RNA Replication</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Drug repurposing</Keyword><Keyword MajorTopicYN="N">Human enteroviruses</Keyword><Keyword MajorTopicYN="N">Pharmacophore</Keyword><Keyword MajorTopicYN="N">Tanomastat</Keyword><Keyword MajorTopicYN="N">VP1 hydrophobic pocket</Keyword></KeywordList><CoiStatement>Declaration of interests HF received grants from Synthetic Biology Translational Research Program, School of Medicine, National University of Singapore.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>7</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>14</Day><Hour>10</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>4</Day><Hour>1</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>3</Day><Hour>18</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39226680</ArticleId><ArticleId IdType="pmc">PMC11419895</ArticleId><ArticleId IdType="doi">10.1016/j.ebiom.2024.105277</ArticleId><ArticleId IdType="pii">S2352-3964(24)00313-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Solomon T., Lewthwaite P., Perera D., Cardosa M.J., McMinn P., Ooi M.H. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis. 2010;10:778–790. doi: 10.1016/S1473-3099(10)70194-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(10)70194-8</ArticleId><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt N.J., Lennette E.H., Ho H.H. An apparently new enterovirus isolated from patients with disease of the central nervous system. J Infect Dis. 1974;129:304–309. doi: 10.1093/infdis/129.3.304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/129.3.304</ArticleId><ArticleId IdType="pubmed">4361245</ArticleId></ArticleIdList></Reference><Reference><Citation>Puenpa J., Wanlapakorn N., Vongpunsawad S., Poovorawan Y. The history of enterovirus A71 outbreaks and molecular epidemiology in the asia-Pacific region. J Biomed Sci. 2019;26:75. doi: 10.1186/s12929-019-0573-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-019-0573-2</ArticleId><ArticleId IdType="pmc">PMC6798416</ArticleId><ArticleId IdType="pubmed">31627753</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang B., Liu F., Liao Q., et al. Epidemiology of hand, foot and mouth disease in China, 2008 to 2015 prior to the introduction of EV-A71 vaccine. Euro Surveill. 2017;22 doi: 10.2807/1560-7917.ES.2017.22.50.16-00824.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2017.22.50.16-00824</ArticleId><ArticleId IdType="pmc">PMC5743100</ArticleId><ArticleId IdType="pubmed">29258646</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagiwara A., Tagaya I., Yoneyama T. Epidemic of hand, foot and mouth disease associated with enterovirus 71 infection. Intervirology. 1978;9:60–63. doi: 10.1159/000148922.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000148922</ArticleId><ArticleId IdType="pubmed">202573</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan L.G., Parashar U.D., Lye M.S., et al. Deaths of children during an outbreak of hand, foot, and mouth disease in sarawak, Malaysia: clinical and pathological characteristics of the disease. For the Outbreak Study Group. Clin Infect Dis. 2000;31:678–683. doi: 10.1086/314032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/314032</ArticleId><ArticleId IdType="pubmed">11017815</ArticleId></ArticleIdList></Reference><Reference><Citation>McMinn P.C. An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev. 2002;26:91–107. doi: 10.1111/j.1574-6976.2002.tb00601.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1574-6976.2002.tb00601.x</ArticleId><ArticleId IdType="pubmed">12007645</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan K.P., Goh K.T., Chong C.Y., Teo E.S., Lau G., Ling A.E. Epidemic hand, foot and mouth disease caused by human enterovirus 71, Singapore. Emerg Infect Dis. 2003;9:78–85. doi: 10.3201/eid0901.020112.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid0901.020112</ArticleId><ArticleId IdType="pmc">PMC2873753</ArticleId><ArticleId IdType="pubmed">12533285</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y., Yeo A., Phoon M.C., et al. The largest outbreak of hand; foot and mouth disease in Singapore in 2008: the role of enterovirus 71 and coxsackievirus A strains. Int J Infect Dis. 2010;14:e1076–e1081. doi: 10.1016/j.ijid.2010.07.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2010.07.006</ArticleId><ArticleId IdType="pubmed">20952237</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho M., Chen E.R., Hsu K.H., et al. An epidemic of enterovirus 71 infection in Taiwan. Taiwan enterovirus epidemic working group. N Engl J Med. 1999;341:929–935. doi: 10.1056/NEJM199909233411301.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199909233411301</ArticleId><ArticleId IdType="pubmed">10498487</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan J., Shen L., Wu J., et al. Enterovirus A71 proteins: structure and function. Front Microbiol. 2018;9:286. doi: 10.3389/fmicb.2018.00286.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2018.00286</ArticleId><ArticleId IdType="pmc">PMC5826392</ArticleId><ArticleId IdType="pubmed">29515559</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura Y., Shimojima M., Tano Y., Miyamura T., Wakita T., Shimizu H. Human P-selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71. Nat Med. 2009;15:794–797. doi: 10.1038/nm.1961.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.1961</ArticleId><ArticleId IdType="pubmed">19543284</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamayoshi S., Yamashita Y., Li J., et al. Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nat Med. 2009;15:798–801. doi: 10.1038/nm.1992.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.1992</ArticleId><ArticleId IdType="pubmed">19543282</ArticleId></ArticleIdList></Reference><Reference><Citation>Baggen J., Thibaut H.J., Strating J., van Kuppeveld F.J.M. The life cycle of non-polio enteroviruses and how to target it. Nat Rev Microbiol. 2018;16:368–381. doi: 10.1038/s41579-018-0005-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-018-0005-4</ArticleId><ArticleId IdType="pubmed">29626210</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C.H., Li H.C., Jiang J.G., et al. Enterovirus type 71 2A protease functions as a transcriptional activator in yeast. J Biomed Sci. 2010;17:65. doi: 10.1186/1423-0127-17-65.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1423-0127-17-65</ArticleId><ArticleId IdType="pmc">PMC2923119</ArticleId><ArticleId IdType="pubmed">20682079</ArticleId></ArticleIdList></Reference><Reference><Citation>Shih S.R., Chiang C., Chen T.C., et al. Mutations at KFRDI and VGK domains of enterovirus 71 3C protease affect its RNA binding and proteolytic activities. J Biomed Sci. 2004;11:239–248. doi: 10.1007/BF02256567.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF02256567</ArticleId><ArticleId IdType="pubmed">14966374</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J., Hu Y., Zheng M. Enterovirus A71 antivirals: past, present, and future. Acta Pharm Sin B. 2022;12:1542–1566. doi: 10.1016/j.apsb.2021.08.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.apsb.2021.08.017</ArticleId><ArticleId IdType="pmc">PMC9279511</ArticleId><ArticleId IdType="pubmed">35847514</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercorelli B., Palu G., Loregian A. Drug repurposing for viral infectious diseases: how far are we? Trends Microbiol. 2018;26:865–876. doi: 10.1016/j.tim.2018.04.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tim.2018.04.004</ArticleId><ArticleId IdType="pmc">PMC7126639</ArticleId><ArticleId IdType="pubmed">29759926</ArticleId></ArticleIdList></Reference><Reference><Citation>Pushpakom S., Iorio F., Eyers P.A., et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019;18:41–58.</Citation><ArticleIdList><ArticleId IdType="pubmed">30310233</ArticleId></ArticleIdList></Reference><Reference><Citation>Parvathaneni V., Kulkarni N.S., Muth A., Gupta V. Drug repurposing: a promising tool to accelerate the drug discovery process. Drug Discov Today. 2019;24:2076–2085.</Citation><ArticleIdList><ArticleId IdType="pubmed">31238113</ArticleId></ArticleIdList></Reference><Reference><Citation>RCSB protein Data Bank. https://www.rcsb.org Available from:</Citation></Reference><Reference><Citation>Schrödinger release 2020-3: protein preparation wizard. Epik, Schrödinger, LLC; New York, NY: 2020. https://www.schrodinger.com/life-science/learn/white-papers/protein-preparation-wizard/ Impact, Schrödinger, LLC, New York, NY; Prime, Schrödinger, LLC, New York, NY, 2020. Available from:</Citation></Reference><Reference><Citation>Bas D.C., Rogers D.M., Jensen J.H. Very fast prediction and rationalization of pKa values for protein-ligand complexes. Proteins: Struct, Funct, Bioinf. 2008;73:765–783. doi: 10.1002/prot.22102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/prot.22102</ArticleId><ArticleId IdType="pubmed">18498103</ArticleId></ArticleIdList></Reference><Reference><Citation>DrugBank. https://go.drugbank.com Available from:</Citation></Reference><Reference><Citation>Roos K., Wu C., Damm W., et al. OPLS3e: Extending force field coverage for drug-like small molecules. J Chem Theory Comput. 2019;15:1863–1874.</Citation><ArticleIdList><ArticleId IdType="pubmed">30768902</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrödinger release 2020-3. LigPrep, Schrödinger, LLC; New York, NY: 2020. https://www.schrodinger.com/platform/products/ligprep/ Available from:</Citation></Reference><Reference><Citation>Salam N.K., Nuti R., Sherman W. Novel method for generating structure-based pharmacophores using energetic analysis. J Chem Inf Model. 2009;49:2356–2368. doi: 10.1021/ci900212v.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ci900212v</ArticleId><ArticleId IdType="pubmed">19761201</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrödinger release 2020-3: Glide. Schrödinger, LLC; New York, NY: 2020. https://www.schrodinger.com/platform/products/glide/ Available from:</Citation></Reference><Reference><Citation>Friesner R.A., Banks J.L., Murphy R.B., et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem. 2004;47:1739–1749.</Citation><ArticleIdList><ArticleId IdType="pubmed">15027865</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrödinger release 2020-3: phase. Schrödinger, LLC; New York, NY: 2020. https://www.schrodinger.com/platform/products/phase/ Available from:</Citation></Reference><Reference><Citation>Pevear D.C., Tull T.M., Seipel M.E., Groarke J.M. Activity of pleconaril against enteroviruses. Antimicrob Agents Chemother. 1999;43:2109–2115. doi: 10.1128/AAC.43.9.2109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.43.9.2109</ArticleId><ArticleId IdType="pmc">PMC89431</ArticleId><ArticleId IdType="pubmed">10471549</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider-Poetsch T., Ju J., Eyler D.E., et al. Inhibition of eukaryotic translation elongation by cycloheximide and lactimidomycin. Nat Chem Biol. 2010;6:209–217. doi: 10.1038/nchembio.304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nchembio.304</ArticleId><ArticleId IdType="pmc">PMC2831214</ArticleId><ArticleId IdType="pubmed">20118940</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray K.E., Nibert M.L. Guanidine hydrochloride inhibits mammalian orthoreovirus growth by reversibly blocking the synthesis of double-stranded RNA. J Virol. 2007;81:4572–4584. doi: 10.1128/JVI.02106-06.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02106-06</ArticleId><ArticleId IdType="pmc">PMC1900160</ArticleId><ArticleId IdType="pubmed">17301147</ArticleId></ArticleIdList></Reference><Reference><Citation>Lv X., Qiu M., Chen D., Zheng N., Jin Y., Wu Z. Apigenin inhibits enterovirus 71 replication through suppressing viral IRES activity and modulating cellular JNK pathway. Antiviral Res. 2014;109:30–41. doi: 10.1016/j.antiviral.2014.06.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2014.06.004</ArticleId><ArticleId IdType="pubmed">24971492</ArticleId></ArticleIdList></Reference><Reference><Citation>Charan J., Kantharia N.D. How to calculate sample size in animal studies? J Pharmacol Pharmacother. 2013;4:303–306. doi: 10.4103/0976-500X.119726.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/0976-500X.119726</ArticleId><ArticleId IdType="pmc">PMC3826013</ArticleId><ArticleId IdType="pubmed">24250214</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandenburg B., Lee L.Y., Lakadamyali M., Rust M.J., Zhuang X., Hogle J.M. Imaging poliovirus entry in live cells. PLoS Biol. 2007;5 doi: 10.1371/journal.pbio.0050183.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.0050183</ArticleId><ArticleId IdType="pmc">PMC1914398</ArticleId><ArticleId IdType="pubmed">17622193</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu K.X., Chu J.J. Antiviral screen identifies EV71 inhibitors and reveals camptothecin-target, DNA topoisomerase 1 as a novel EV71 host factor. Antiviral Res. 2017;143:122–133. doi: 10.1016/j.antiviral.2017.04.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2017.04.008</ArticleId><ArticleId IdType="pubmed">28427827</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunaseelan S., Wong K.Z., Min N., et al. Prunin suppresses viral IRES activity and is a potential candidate for treating enterovirus A71 infection. Sci Transl Med. 2019;11 doi: 10.1126/scitranslmed.aar5759.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aar5759</ArticleId><ArticleId IdType="pubmed">31666401</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowinsky E.K., Humphrey R., Hammond L.A., et al. Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies. J Clin Oncol. 2000;18:178–186. doi: 10.1200/JCO.2000.18.1.178.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2000.18.1.178</ArticleId><ArticleId IdType="pubmed">10623708</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., Yuan M., Yang E., Chen D., Su A., Wu Z. Enterovirus 71 infection induced Aquaporin-4 depolarization by increasing matrix metalloproteinase-9 activity. Neurosci Lett. 2021;759 doi: 10.1016/j.neulet.2021.136049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2021.136049</ArticleId><ArticleId IdType="pubmed">34126180</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan Y.W., Yam W.K., Sun J., Chu J.J.H. An evaluation of chloroquine as a broad-acting antiviral against hand, foot and mouth disease. Antiviral Res. 2018;149:143–149. doi: 10.1016/j.antiviral.2017.11.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2017.11.017</ArticleId><ArticleId IdType="pubmed">29175128</ArticleId></ArticleIdList></Reference><Reference><Citation>Cena-Diez R., Singh K., Spetz A.L., Sonnerborg A. Novel naturally occurring dipeptides and single-stranded oligonucleotide act as entry inhibitors and exhibit a strong synergistic anti-HIV-1 profile. Infect Dis Ther. 2022;11:1103–1116. doi: 10.1007/s40121-022-00626-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40121-022-00626-8</ArticleId><ArticleId IdType="pmc">PMC9124260</ArticleId><ArticleId IdType="pubmed">35391633</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu J., He Y.Q., Yi L.N., Zan H., Kung H.F., He M.L. Viral kinetics of enterovirus 71 in human abdomyosarcoma cells. World J Gastroenterol. 2011;17:4135–4142. doi: 10.3748/wjg.v17.i36.4135.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v17.i36.4135</ArticleId><ArticleId IdType="pmc">PMC3203367</ArticleId><ArticleId IdType="pubmed">22039330</ArticleId></ArticleIdList></Reference><Reference><Citation>De Colibus L., Wang X., Spyrou J.A.B., et al. More-powerful virus inhibitors from structure-based analysis of HEV71 capsid-binding molecules. Nat Struct Mol Biol. 2014;21:282–288. doi: 10.1038/nsmb.2769.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsmb.2769</ArticleId><ArticleId IdType="pmc">PMC4530014</ArticleId><ArticleId IdType="pubmed">24509833</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossmann M.G. Viral cell recognition and entry. Protein Sci. 1994;3:1712–1725. doi: 10.1002/pro.5560031010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pro.5560031010</ArticleId><ArticleId IdType="pmc">PMC2142612</ArticleId><ArticleId IdType="pubmed">7849588</ArticleId></ArticleIdList></Reference><Reference><Citation>Shingler K.L., Yoder J.L., Carnegie M.S., et al. The enterovirus 71 A-particle forms a gateway to allow genome release: a cryoEM study of picornavirus uncoating. PLoS Pathog. 2013;9 doi: 10.1371/journal.ppat.1003240.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1003240</ArticleId><ArticleId IdType="pmc">PMC3605244</ArticleId><ArticleId IdType="pubmed">23555253</ArticleId></ArticleIdList></Reference><Reference><Citation>Anasir M.I., Zarif F., Poh C.L. Antivirals blocking entry of enteroviruses and therapeutic potential. J Biomed Sci. 2021;28:10. doi: 10.1186/s12929-021-00708-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-021-00708-8</ArticleId><ArticleId IdType="pmc">PMC7811253</ArticleId><ArticleId IdType="pubmed">33451326</ArticleId></ArticleIdList></Reference><Reference><Citation>Oberste M.S., Maher K., Flemister M.R., Marchetti G., Kilpatrick D.R., Pallansch M.A. Comparison of classic and molecular approaches for the identification of untypeable enteroviruses. J Clin Microbiol. 2000;38:1170–1174. doi: 10.1128/JCM.38.3.1170-1174.2000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.38.3.1170-1174.2000</ArticleId><ArticleId IdType="pmc">PMC86366</ArticleId><ArticleId IdType="pubmed">10699015</ArticleId></ArticleIdList></Reference><Reference><Citation>Oberste M.S., Maher K., Kilpatrick D.R., Pallansch M.A. Molecular evolution of the human enteroviruses: correlation of serotype with VP1 sequence and application to picornavirus classification. J Virol. 1999;73:1941–1948. doi: 10.1128/JVI.73.3.1941-1948.1999.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.73.3.1941-1948.1999</ArticleId><ArticleId IdType="pmc">PMC104435</ArticleId><ArticleId IdType="pubmed">9971773</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown B.A., Maher K., Flemister M.R., et al. Resolving ambiguities in genetic typing of human enterovirus species C clinical isolates and identification of enterovirus 96, 99 and 102. J Gen Virol. 2009;90:1713–1723. doi: 10.1099/vir.0.008540-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.008540-0</ArticleId><ArticleId IdType="pubmed">19264596</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y.L., Lin T.M., Wang S.Y., Wang J.R. The role of conserved arginine and proline residues in enterovirus VP1 protein. J Microbiol Immunol Infect. 2022;55:590–597. doi: 10.1016/j.jmii.2022.01.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmii.2022.01.004</ArticleId><ArticleId IdType="pubmed">35232679</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J., Ye X., Zhang X.Y., et al. Coxsackievirus A10 atomic structure facilitating the discovery of a broad-spectrum inhibitor against human enteroviruses. Cell Discov. 2019;5:4. doi: 10.1038/s41421-018-0073-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41421-018-0073-7</ArticleId><ArticleId IdType="pmc">PMC6331555</ArticleId><ArticleId IdType="pubmed">30652025</ArticleId></ArticleIdList></Reference><Reference><Citation>Debing Y., Neyts J., Delang L. The future of antivirals: broad-spectrum inhibitors. Curr Opin Infect Dis. 2015;28:596–602. doi: 10.1097/QCO.0000000000000212.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QCO.0000000000000212</ArticleId><ArticleId IdType="pubmed">26524332</ArticleId></ArticleIdList></Reference><Reference><Citation>Pevear D.C., Hayden F.G., Demenczuk T.M., Barone L.R., McKinlay M.A., Collett M.S. Relationship of pleconaril susceptibility and clinical outcomes in treatment of common colds caused by rhinoviruses. Antimicrob Agents Chemother. 2005;49:4492–4499. doi: 10.1128/AAC.49.11.4492-4499.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.49.11.4492-4499.2005</ArticleId><ArticleId IdType="pmc">PMC1280128</ArticleId><ArticleId IdType="pubmed">16251287</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho J.Y., Chern J.H., Hsieh C.F., et al. In vitro and in vivo studies of a potent capsid-binding inhibitor of enterovirus 71. J Antimicrob Chemother. 2016;71:1922–1932. doi: 10.1093/jac/dkw101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkw101</ArticleId><ArticleId IdType="pubmed">27098012</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y., Lei E., Li L., et al. Antiviral activity of Mulberroside C against enterovirus A71 in vitro and in vivo. Eur J Pharmacol. 2021;906 doi: 10.1016/j.ejphar.2021.174204.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2021.174204</ArticleId><ArticleId IdType="pubmed">34051220</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin W.Y., Yu Y.J., Jinn T.R. Evaluation of the virucidal effects of rosmarinic acid against enterovirus 71 infection via in vitro and in vivo study. Virol J. 2019;16:94. doi: 10.1186/s12985-019-1203-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-019-1203-z</ArticleId><ArticleId IdType="pmc">PMC6670152</ArticleId><ArticleId IdType="pubmed">31366366</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang G., Zhou F., Gu B., et al. In vitro and in vivo evaluation of ribavirin and pleconaril antiviral activity against enterovirus 71 infection. Arch Virol. 2012;157:669–679. doi: 10.1007/s00705-011-1222-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-011-1222-6</ArticleId><ArticleId IdType="pubmed">22245989</ArticleId></ArticleIdList></Reference><Reference><Citation>Rotbart H.A. Antiviral therapy for enteroviruses and rhinoviruses. Antivir Chem Chemother. 2000;11:261–271. doi: 10.1177/095632020001100402.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/095632020001100402</ArticleId><ArticleId IdType="pubmed">10950388</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayden F.G., Herrington D.T., Coats T.L., et al. Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: results of 2 double-blind, randomized, placebo-controlled trials. Clin Infect Dis. 2003;36:1523–1532. doi: 10.1086/375069.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/375069</ArticleId><ArticleId IdType="pmc">PMC7199898</ArticleId><ArticleId IdType="pubmed">12802751</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark T.G., Bradburn M.J., Love S.B., Altman D.G. Survival analysis part I: basic concepts and first analyses. Br J Cancer. 2003;89:232–238. doi: 10.1038/sj.bjc.6601118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.bjc.6601118</ArticleId><ArticleId IdType="pmc">PMC2394262</ArticleId><ArticleId IdType="pubmed">12865907</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong K.C., Wong K.T. Understanding enterovirus 71 neuropathogenesis and its impact on other neurotropic enteroviruses. Brain Pathol. 2015;25:614–624. doi: 10.1111/bpa.12279.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12279</ArticleId><ArticleId IdType="pmc">PMC8029433</ArticleId><ArticleId IdType="pubmed">26276025</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirte H., Goel R., Major P., et al. A phase I dose escalation study of the matrix metalloproteinase inhibitor BAY 12-9566 administered orally in patients with advanced solid tumours. Ann Oncol. 2000;11:1579–1584. doi: 10.1023/a:1008347630465.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/a:1008347630465</ArticleId><ArticleId IdType="pubmed">11205466</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirte H., Vergote I.B., Jeffrey J.R., et al. A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Trials Group Study. Gynecol Oncol. 2006;102:300–308. doi: 10.1016/j.ygyno.2005.12.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ygyno.2005.12.020</ArticleId><ArticleId IdType="pubmed">16442153</ArticleId></ArticleIdList></Reference><Reference><Citation>Molina J.R., Reid J.M., Erlichman C., et al. A phase I and pharmacokinetic study of the selective, non-peptidic inhibitor of matrix metalloproteinase BAY 12-9566 in combination with etoposide and carboplatin. Anti Cancer Drugs. 2005;16:997–1002. doi: 10.1097/01.cad.0000176504.86551.5c.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.cad.0000176504.86551.5c</ArticleId><ArticleId IdType="pubmed">16162976</ArticleId></ArticleIdList></Reference><Reference><Citation>Erlichman C., Adjei A.A., Alberts S.R., et al. Phase I study of the matrix metalloproteinase inhibitor, BAY 12-9566. Ann Oncol. 2001;12:389–395. doi: 10.1023/a:1011183905848.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/a:1011183905848</ArticleId><ArticleId IdType="pubmed">11332153</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>